Feature | May 20, 2015

Botox Injections Help Prevent Atrial Fibrillation After Cardiac Surgery

Study finds botulinum toxin injections in epicardial fat pads reduce AF risk immediately following surgery and after one year of follow-up

botox, atrial fibrillation, cardiac surgery, HRS

May 20, 2015 — A study presented at Heart Rhythm 2015 found that botulinum toxin (botox) injections into epicardial fat pads during coronary artery bypass graft (CABG) surgery can be beneficial for the patient. The injection not only reduces the incidence of post-operative atrial fibrillation (AF), but also provides substantial AF suppression after one year.

Heart Rhythm 2015 is the Heart Rhythm Society’s 36th annual scientific sessions, May 13-16 in Boston.  

AF is the most common arrhythmia complicating cardiac surgery and occurs in approximately 30-40 percent of patients undergoing CABG surgery. CABG is the most common type of open-heart surgery in the United States and improves blood flow to the heart to treat people with coronary heart disease. Patients who develop AF after cardiac surgery are at an increased risk of stroke and congestive heart failure.

The prospective, double-blind study randomized 60 patients with a history of paroxysmal AF undergoing CABG to receive either botox injections or a saline placebo injection during surgery. Patients were followed for one year to assess maintenance of sinus rhythm using an implantable loop recorder. All patients in both groups had successful epicardial fat pad injections without complications and with minimal additional surgery time. 

The incidence of early postoperative AF within 30 days after surgery was two patients (7 percent) in the botox group compared to nine patients (30 percent) in the placebo group. Between the 30-day period and up to the 12-month follow-up examination, seven of the 30 patients in the placebo group (27 percent) had recurrent AF, while no patients in the botox group (0 percent) experienced recurrent AF. Further, there were no complications observed during the one year follow-up. 

“Currently, there are no therapies available to reduce AF after open heart surgery, so the study results are very promising and help fulfill an unmet need in cardiology care,” said lead author Evgeny Pokushalov, M.D., Ph.D., State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation. “Botox injections in the epicardial fat pads have the potential to become standard of care for patients undergoing open heart surgery and provide a new opportunity to reduce AF and associated complications.”

The lead authors call for a large, multi-center study to assess the safety and efficacy of botox injections in the epicardial fat pads for AF prevention and to further showcase the clinical benefit of this technique.

For more information: www.hrsonline.org

Related Content

News | Cardiovascular Surgery

April 29, 2022 – Paragonix Technologies, Inc., a leading organ preservation provider, announces today groundbreaking ...

Home April 29, 2022
Home
News | Cardiovascular Surgery
January 18, 2022 – Evonik Venture Capital has invested in CircumFix Solutions, a Tennessee-based start-up that has ...
Home February 18, 2022
Home
News | Cardiovascular Surgery
February 15, 2022 – A multicenter, retrospective database analysis suggests improved open abdominal aortic aneurysm (AAA ...
Home February 15, 2022
Home
News | Cardiovascular Surgery

February 11, 2022 — Riverside Community Hospital has earned a distinguished three-star rating from The Society of ...

Home February 11, 2022
Home
News | Cardiovascular Surgery

November 23, 2021 — A novel device called venous external support (VEST) may lead to increased longevity and durability ...

Home November 23, 2021
Home
News | Cardiovascular Surgery

November 22, 2021 — The Minneapolis Heart Institute Foundation (MHIF) announced the publication of research showing ...

Home November 22, 2021
Home
News | Cardiovascular Surgery

November 18, 2021 — Moderna Inc. announced positive data from the AstraZeneca-led Phase 2 (EPICCURE) study evaluating ...

Home November 18, 2021
Home
News | Cardiovascular Surgery

November 18, 2021 — People who are on the antiplatelet medication ticagrelor and need coronary artery bypass surgery may ...

Home November 18, 2021
Home
Feature | Cardiovascular Surgery | By Noam Emanuel, Ph.D.

Surgical Site Infection (SSI) prevention remains a high priority for cardiac surgeons whose heroic efforts can be ...

Home June 24, 2021
Home
News | Cardiovascular Surgery

April 5, 2021 — Smidt Heart Institute transplant surgeons Dominic Emerson, M.D., and Pedro Catarino, M.D. know how to be ...

Home April 05, 2021
Home
Subscribe Now